Patia

Genetic Testing Servicespatiadiabetes.com

Patia (PATIA EUROPE S.L.) is a Spanish biotech that sells patented SNP-based genetic tests (DIABETESpredict, MATERgen, Diabegen) for diabetes risk, gestational diabetes, and precision medicine, serving consumers, clinicians, and corporate wellness programs primarily in Spain and Mexico/LATAM.

Company typePrivate
Founded2019
HeadquartersDonostia-san Sebastián, Spain
Headcount11–50
GTM typeB2B and B2C
OfferingServices

What Patia does

Patia (PATIA EUROPE S.L.) is a Spanish biotechnology company headquartered in Donostia-San Sebastián that develops and commercializes patented SNP-based genetic testing products for the prevention and management of diabetes. Its three core products—DIABETESpredict (type 2 diabetes risk assessment across 16 SNPs in 16 genes, clinically validated in 8,000+ multiethnic patients and published in Nature Scientific Reports 2019 with AUC 0.82), MATERgen (21 DNA variants for gestational diabetes risk and pregnancy-related folate/B12 metabolism), and Diabegen (precision medicine for patients with prediabetes or type 2 diabetes)—are delivered as at-home buccal/blood sample kits with genotype-informed recommendations on nutrition, physical activity, supplements, and pharmacology.

The company runs a hybrid B2B/B2C go-to-market model. Direct-to-consumer sales are conducted via website kit request forms, phone, WhatsApp, and email, targeting health-conscious individuals, women planning pregnancy, and at-risk populations. B2B revenue is generated through corporate social responsibility (RSC) wellness programs at large enterprises (BBVA Bancomer, Abbott Laboratories, Michelin, Cuatrecasas, Geroa) and public-sector health initiatives (Ayuntamiento de Murcia, Bic Gipuzkoa, Gipuzkoa Provincial Council). Geographic focus is Spain and Mexico/LATAM, with secondary presence in the USA via patiadiabetes.us.

Revenue mechanics rely on one-time genetic testing kit sales and periodic retesting under quote-based pricing with no publicly disclosed tiers. R&D is funded primarily through non-dilutive public grants from the Basque Government (HAZITEK programme), the Spanish Ministry of Science and Innovation, and EU FEDER funds, with no private venture or growth equity disclosed. Scientific collaborations span Massachusetts General Hospital, Broad Institute, Hospital Clínico San Carlos, and Hospital de la Santa Creu i Sant Pau, and a December 2023 technology partnership with Basque startup Glucovibes extends the DIABETESpredict output into an integrated multi-modal health report combining continuous glucose monitoring, activity, nutrition, and sleep data.

Patia firmographics

Firmographics

Name: Patia
Legal name: PATIA EUROPE S.L.
Website: https://patiadiabetes.com
Company type: Private
Founded year: 2019
Operating status: Operating
Headcount range: 11–50 employees
Short description: Patia (PATIA EUROPE S.L.) is a Spanish biotech that sells patented SNP-based genetic tests (DIABETESpredict, MATERgen, Diabegen) for diabetes risk, gestational diabetes, and precision medicine, serving consumers, clinicians, and corporate wellness programs primarily in Spain and Mexico/LATAM.
Ownership category
akta.pro rank

Patia industry classification

Industry

Product category: Genetic Testing Services
NAICS: Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry: Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
akta.pro secondary industry: Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

Genetic testing services
Diabetes prevention
Precision medicine diagnostics
Gestational diabetes screening
SNP genetic analysis

Where Patia is headquartered

Location

Headquarters

HQ city: Donostia-san Sebastián
HQ country: Spain
HQ region: Europe

Offices1 record

Markets served

Patia business model

Business model

GTM type: B2B and B2C
Offering type: Services
Cost components: Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

Genetic Testing Kits and Reports: One-time genetic testing services (DIABETESpredict, Diabegen, MATERgen) with single-use or periodic testing frequency. Products sold as test kits with results reports including genetic profile and personalized recommendations. Additional revenue from corporate RSC programs offering employee genetic screening.

Pricing tiers

Model	Billing	Price
Other	Pay-as-you-go	Genetic testing products sold individually or as bundled kits

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Patia product offering

Product offering

Core offering

Patia develops and sells three proprietary genetic testing kits — DIABETESpredict (type 2 diabetes risk), Diabegen (precision medicine for prediabetes and type 2 diabetes), and MATERgen (gestational diabetes and pregnancy health) — that analyze DNA variants via patented algorithms and produce personalized recommendations on nutrition, physical activity, supplements, and pharmacology. Patia also deploys these tests through Corporate Social Responsibility (RSC) health and wellness programs for enterprise and public-sector clients.

Product overview

Patia offers a suite of three genetic testing products for diabetes prevention and management. DIABETESpredict™ provides genetic risk assessment for type 2 diabetes with lifestyle recommendations. Diabegen™ serves as a precision medicine tool for managing existing prediabetes or type 2 diabetes through personalized intervention guidance. MATERgen™ focuses on gestational diabetes prevention and healthy pregnancy outcomes. All three products leverage patented technology and integrate genetic analysis with clinical data to deliver personalized recommendations.

Differentiator

Problem solved

Functional benefit

Brands

DIABETESpredict: Genetic test evaluating predisposition to develop type 2 diabetes, offering genotype-informed recommendations for prevention. Analyses 16 SNP in 16 genes. Clinically validated with AUC of 0.82, sensitivity 73%, specificity 78%.
MATERgen
Diabegen

Products and services

DIABETESpredict™ Genetic test evaluating predisposition to develop type 2 diabetes by analyzing 16 SNPs in 16 genes and delivering personalized prevention recommendations on nutrition and lifestyle based on individual genotype. Validated with AUC 0.82, sensitivity 73%, and specificity 78% in 8,000+ multiethnic patients. Intended for at-risk individuals seeking early risk assessment.
Diabegen™ Precision-medicine genetic test analyzing 16 SNPs in 16 genes associated with type 2 diabetes pathophysiology to provide individualized intervention information — covering physical activity, nutrition, supplements, and pharmacology — for disease management in people with prediabetes or diagnosed type 2 diabetes.
MATERgen™ Genetic test analyzing 21 DNA variants associated with glucose management, insulin resistance, pancreatic structure and function, folic acid metabolism (MTHFR polymorphisms, present in 40-60% of women), and vitamin B12 processing. Detects gestational diabetes risk, folic acid metabolism alterations, and elevated homocysteine predisposition to prevent premature births, malformations, and other pregnancy complications.

Quantifiable outcome

AUC 0.82, Sensitivity 73%, Specificity 78% for type 2 diabetes risk prediction (Nature Scientific Reports 2019, 9(1):2748)
+3 more outcomes

Companies that use Patia

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles4 records

Patia technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature4 records

Patia partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

GlucovibescoreTechnology or Integration · 21 December 2023Patia and Glucovibes formed a technology partnership combining genetic test results (DIABETESpredict) with continuous glucose monitoring, physical activity, nutrition, and sleep tracking. The integrated kit provides a multidisciplinary approach to pathology prevention and quality of life improvement, offering precision nutrition recommendations based on DNA, glucose, and lifestyle data. Both are Basque scientific start-ups.
Massachusetts General Hospital (MGH)coreStrategic or Co-development PartnerResearch collaboration in I+D projects. MGH is listed among Patia's R&D partners (displayed as logo) alongside Broad Institute and other prestigious institutions, indicating scientific collaboration in diabetes genetics research.
Broad InstitutecoreStrategic or Co-development PartnerResearch collaboration in I+D projects. Broad Institute is listed among Patia's R&D partners, indicating involvement in genetic research for diabetes prevention and treatment.
Hospital Clínico San CarloscoreStrategic or Co-development PartnerListed as an R&D partner (displayed as logo) collaborating with Patia on genetic research related to diabetes prevention and clinical validation.
Hospital de la Santa Creu i Sant PaucoreStrategic or Co-development PartnerListed as an R&D partner (displayed as logo) collaborating on genetic research and clinical studies related to diabetes.
Fundación Carlos SlimminorStrategic or Co-development PartnerListed as an R&D partner (displayed as logo). Given the Mexican/LATAM market focus of Fundación Carlos Slim, this partnership likely supports Patia's Mexico/LATAM expansion and research activities in Latin America.
Gobierno Vasco / Basque GovernmentcoreStrategic or Co-development PartnerCo-financing partner for multiple R&D projects (SUPREME, DTRES proiektua, SMARTMED) under the HAZITEK program, funded through FEDER (Fondo Europeo de Desarrollo Regional).
Ministerio de Ciencia e Innovación / Agencia Estatal de InvestigacióncoreStrategic or Co-development PartnerPublic funding agency supporting DIABETES2PREVENT (CPP2021-008725) and PREDIGEST (RTC2019-007406-1) projects. Both are publicly funded collaborative R&D initiatives in precision medicine for diabetes.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Patia competitors and assessment

Company assessment

Direct peers

deCODE genetics (Amgen): Iceland-based genetics company (Amgen subsidiary) pioneering population-scale genetic risk assessment for common diseases including type 2 diabetes. Closest comparable in disease-risk genetic testing methodology and clinical validation approach.
Prenetics (CircleDNA): Asia-based direct-to-consumer genetic testing company (CircleDNA brand) offering health-focused DNA tests. Closely comparable D2C health-genetics business model and product positioning.
Newtopia: Corporate wellness platform combining genetic risk assessment with personalized coaching for chronic disease prevention. Closely comparable on the corporate RSC / B2B wellness distribution channel Patia uses with BBVA, Michelin, and Cuatrecasas.
23andMe: Direct-to-consumer genetic testing platform with health predisposition reports including type 2 diabetes risk. Closest comparable in the D2C genetic health risk model that Patia also operates, though 23andMe is far broader in scope.
Genomics plc: UK-based company commercializing polygenic risk scores for common disease prediction, including type 2 diabetes. Highly comparable on the algorithmic, multi-SNP disease-risk prediction model Patia uses in DIABETESpredict.
Invitae: Clinical genetic testing company offering hereditary disease risk and pharmacogenomic tests. Comparable in clinical-grade genetic testing services, particularly relevant to Patia's Diabegen pharmacogenomic precision medicine line.
Myriad Genetics: US clinical genetic testing company with hereditary disease risk tests. Comparable in clinical-grade genetic risk testing for disease predisposition, with deeper regulatory and reimbursement infrastructure.

Emerging players

Viome: D2C health-testing company focused on microbiome and metabolic health with personalized nutrition recommendations. Comparable on the genotype/phenotype-informed precision nutrition value proposition Patia delivers through Diabegen.

Broad incumbents

Ancestry: Largest D2C genetic testing company by volume (ancestry-focused). Competes for the same consumer wallet share and corporate wellness budgets despite a less health-centric product portfolio; significantly larger scale.

Regional players

EasyDNA: European/Spanish-market direct-to-consumer genetic testing provider. Comparable regional competitor in Iberia for D2C DNA test kits and health predisposition reports.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Patia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Patia leadership team

Management profile

Number of profiles

Profiles4 records

Patia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Patia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Patia

What does Patia do?

Is Patia a public or private company?

Patia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Patia founded?

Patia was founded in 2019. It employs 11 to 50 people.

Where is Patia based?

Patia is headquartered in Donostia-san Sebastián, Spain, in the Europe region.

How does Patia make money?

One revenue line is on record: genetic Testing Kits and Reports.

Who are Patia's main competitors?

Direct peers on record are deCODE genetics (Amgen), Prenetics (CircleDNA), Newtopia, 23andMe, Genomics plc, Invitae and Myriad Genetics. Viome is listed as an emerging player. Ancestry is listed as a broad incumbent. EasyDNA is listed as a regional player.

Does Patia have an API?

No public API is recorded for Patia.

What industry is Patia in?

Patia's product category is Genetic Testing Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.